Avalo Therapeutics, Inc.

AVTX · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$35-$32-$42-$84
Dep. & Amort.$0$0$0$2
Deferred Tax$0$0$0$0
Stock-Based Comp.$6$3$0$8
Change in WC-$5-$9-$0$3
Other Non-Cash-$15$6$15$1
Operating Cash Flow-$49-$31-$27-$71
Investing Activities
PP&E Inv.$0-$0-$0-$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0-$0-$0-$0
Financing Activities
Debt Repay.$0-$21-$15$33
Stock Issued$116$46$0$72
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$60$0$0$2
Financing Cash Flow$176$25-$15$107
Forex Effect$0$0$0$0
Net Chg. in Cash$127-$6-$41$36
Supplemental Information
Beg. Cash$8$13$55$19
End Cash$135$8$13$55
Free Cash Flow-$49-$31-$27-$71
Avalo Therapeutics, Inc. (AVTX) Financial Statements & Key Stats | AlphaPilot